Clinical trials: Treatment Resistant Major Depression Disorder
Major Depressive Disorder, Treatment Resistant Depression
Antidepressant Effects of Nitrous Oxide
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and…
- Trial name
- NCT05357040
- Testing
- Nitrous oxide gas for inhalation
- Where
- 2 sites in United States, Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Psychiatric Disorder, Major Depressive Disorder
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
- Conditions
- Psychiatric Disorder, Major Depressive Disorder, Metabolic Disorder
- Trial name
- NCT06331572
- Testing
- 17-HAMD
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Treatment-Resistant Major Depressive Disorder
Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression…
- Trial name
- NCT07052058
- Testing
- Tocilizumab, Normal Saline (0.9% NaCl)
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Depression, Major Depressive Disorder
Reward Emotion Learning and Ketamine Study
Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described.
- Conditions
- Depression, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- RELAKS (NCT04850911)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Major Depression Moderate, Major Depression Severe
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07748091
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Major Depression
Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET
This study aims at evaluating the effect of electroconvulsive therapy in treatment-resistant depressed patients on the major serotonin degrading enzyme in the human brain using neuroimaging methods, the monoamine oxidase A.
- Trial name
- NCT02379767
- Testing
- Electroconvulsive therapy, Positron emission tomography of the brain using [11C]harmine, Structural magnetic resonance imaging
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Major Depressive Disorders
The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMSEYE (NCT06615804)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Treatment Resistant Depression, Depression - Major Depressive Disorder
Characterizing Synaptic Density in Treatment Resistant Depression
The purpose of this study is to better understand how certain brain systems work in people with depression, especially in those whose symptoms have not improved with antidepressant treatments.
- Trial name
- TPET (NCT03537794)
- Testing
- PET scans
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Major Depressive Disorder
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24-hour post-injection on resting state functional connectivity, cognitive control, and reward learning.
- Trial name
- NCT04239963
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as…
- Trial name
- NCT02994433
- Testing
- Nitrous Oxide, MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients
Depression is the leading cause of disability worldwide and around 800,000 suicides occur each year. According to the World Health Organization, major depressive disorder (MDD) is expected to be the leading cause of the global…
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Sham-controlled
- Trial name
- NCT06783361
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ataturk University